Gboyega Adeboyeje

机构：Merck & Co., Inc., Rahway, NJ, USA (United States), Merck Biopharma Co., Ltd. (Japan) · ORCID：0000-0002-1088-751X

发表论文 44 篇 · 总被引 246 次 · h-index 7

代表论文

• Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation (2017 · Journal of Managed Care & Specialty Pharmacy · 被引 120)
• A comprehensive literature review and meta‐analysis of the prevalence of pan‐cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies (2022 · Environmental and Molecular Mutagenesis · 被引 39)
• Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban (2018 · PLoS ONE · 被引 16)
• Barriers to next-generation sequencing despite increased utilization: U.S. physician survey results. (2021 · Journal of Clinical Oncology · 被引 11)
• Reducing Overuse of Colony-Stimulating Factors in Patients With Lung Cancer Receiving Chemotherapy: Evidence From a Decision Support–Enabled Program (2017 · Journal of Oncology Practice · 被引 11)
• A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer (2022 · Journal of Oncology · 被引 10)